Here is Why BioMarin (BMRN) is Projected to Rally [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
On March 11, Bank of America Securities reduced its price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from $97 to $85. The firm maintained a Buy rating on the stock, which now yields an adjusted upside of almost 54% despite the downward revision. Likoper/Shutterstock.com The firm stated that more cautious assumptions in the Voxzogo-franchise tail caused it to lower its outlook for the pro-forma entity. This comes prior to the conclusion of BioMarin's acquisition of Amicus Therapeutics Inc. (NASDAQ:FOLD), scheduled during the second quarter. Back on February 26, Whitney Ijem from Canaccord Genuity maintained her Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). The analyst also increased her price target from $98 to $104, leading to an upside potential of 88% at the prevailing level. Ijem noted that the company's fourth-quarter results included a slight top-line beat but were otherwise uneventful. This followed the announcement around the company's acquisition
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- BioMarin Pharmaceutical (BMRN) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".MarketBeat
- BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy [Seeking Alpha]Seeking Alpha
- BioMarin Pharmaceutical (BMRN) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d+)" to "hold (c-)".MarketBeat
- BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical (BMRN) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
BMRN
Earnings
- 2/23/26 - Beat
BMRN
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- BMRN's page on the SEC website